MALVERN, Pa., Jan. 10, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today reported that preliminary fourth quarter 2010 total net revenue was $61.8 million, up 28.7% compared with $48.0 million in the fourth quarter of 2009. For the full year 2010, preliminary total net revenue was $211.4 million, up 28.9% compared with $164.0 million in 2009.
"We are energized by the significant progress that Auxilium made in 2010. We achieved record revenues for Testim®, launched XIAFLEX® in the U.S. for Dupuytren's contracture, received a positive CHMP opinion with our EU partner, Pfizer, for XIAFLEX for Dupuytren's contracture, and initiated XIAFLEX global phase III clinical trials for Peyronie's disease," said Armando Anido, Chief Executive Officer and President of Auxilium. "As we look forward to 2011 and beyond, we expect Testim revenues to continue to grow and believe that the potential global market for XIAFLEX represents a blockbuster opportunity, which could provide sustainable long-term growth for the Company."
Preliminary Fourth Quarter 2010 Revenue DetailsAuxilium reported the following unaudited net revenues (all amounts in millions of dollars) for the quarter ended December 31, 2010: Quarter EndQuarter EndIncrease12/31/201012/31/2009(Decrease)Testim U.S. Revenue
$52.1$42.223.3%Testim Ex – U.S. & Contract Revenue
1.34.9(73.7%)Total Testim Revenue
$53.4$47.113.3%XIAFLEX U.S. Revenue
$7.3n/an/aXIAFLEX Contract Revenue
1.10.922.1%Total XIAFLEX Revenue
$8.4$0.9845.0%Total Worldwide Revenue
$61.8$48.028.7%Contract Revenues represent amortization of previously received upfront and milestone payments.
Preliminary 2010 Revenue DetailsAuxilium reported the following unaudited net revenues
|SOURCE Auxilium Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved